OptimizeRx Co. (NASDAQ:OPRX) Receives $10.42 Consensus Target Price from Analysts

Shares of OptimizeRx Co. (NASDAQ:OPRX) have received a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $10.42.

A number of brokerages recently weighed in on OPRX. Stifel Nicolaus dropped their price objective on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Barclays lowered their price target on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, November 14th. JMP Securities reduced their price objective on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a research note on Thursday, November 14th. Roth Mkm restated a “buy” rating and issued a $16.00 target price (down from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th.

Institutional Investors Weigh In On OptimizeRx

A number of institutional investors and hedge funds have recently modified their holdings of OPRX. Vanguard Group Inc. lifted its position in OptimizeRx by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock valued at $12,482,000 after purchasing an additional 6,291 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of OptimizeRx by 9.9% in the second quarter. Bank of New York Mellon Corp now owns 111,719 shares of the company’s stock worth $1,117,000 after buying an additional 10,041 shares during the last quarter. Summit Securities Group LLC acquired a new stake in OptimizeRx during the second quarter worth about $25,000. Legato Capital Management LLC grew its holdings in OptimizeRx by 74.0% during the second quarter. Legato Capital Management LLC now owns 59,693 shares of the company’s stock worth $597,000 after acquiring an additional 25,377 shares during the period. Finally, Rhumbline Advisers raised its position in OptimizeRx by 9.2% during the second quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock valued at $315,000 after acquiring an additional 2,658 shares in the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Price Performance

NASDAQ OPRX opened at $4.99 on Monday. The company has a market cap of $91.92 million, a PE ratio of -3.75 and a beta of 1.34. OptimizeRx has a 52-week low of $3.78 and a 52-week high of $16.65. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The firm’s 50 day moving average price is $5.55 and its 200-day moving average price is $8.07.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.